SCHEMBL7067985

SCHEMBL7067985

Cc1cc(O)n2nc(-c3ccccc3)cc2n1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.74
NPC1 O15118 14/20 0.71
RAB9A P51151 14/20 0.71
KDM4E B2RXH2 7/20 0.71
ALDH1A1 P00352 8/20 0.68
SMN1; SMN2 Q16637 7/20 0.68
HPGD P15428 6/20 0.68
NFKB1 P19838 1/20 0.68
HTT P42858 1/20 0.68
NFKB2 Q00653 1/20 0.68
RELA Q04206 1/20 0.68
HCRTR1 O43613 1/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
GAA P10253 2/20 0.51
ATM Q13315 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704457 0.87 NPC1 (0.71) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL462950 0.86 NPC1 (0.57) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL13977780 0.84 NPC1 (0.73) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL5270613 0.83 NPC1 (1.00) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL13541890 0.83 MAPT (0.55) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL5382159 0.81 DPP4 (0.51) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL7063800 0.81 RAB9A (0.71) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL7436883 0.80 MAPT (0.52) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL1665475 0.79 MAPT (0.63) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL18501695 0.78 NPC1 (0.68) MAPTNPC1RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649759-B2 Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders PFIZER INC. 2003-11-18 US disclosed
US-20030100546-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2003-05-29 US disclosed
US-20020061897-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2002-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100546-A1 Neuropeptide Y antagonists NPY1R, NPY2R, GIPR MAPT 4324/4885NPC1 536/4885RAB9A 1870/4885
US-20020061897-A1 Neuropeptide Y antagonists NPY1R, NPY2R, GIPR MAPT 4324/4885NPC1 536/4885RAB9A 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.